Amiloride: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Potassium-sparing diuretic *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: Midamor ==Adult Dosing== *5-20 mg PO daily ==Ped...") |
(added dosage form) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Potassium-sparing [[diuretic]] | *Type: Potassium-sparing [[diuretic]] | ||
*Dosage Forms: | *Dosage Forms: tablet | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: Midamor | *Common Trade Names: Midamor | ||
Latest revision as of 19:28, 11 October 2017
Administration
- Type: Potassium-sparing diuretic
- Dosage Forms: tablet
- Routes of Administration: Oral
- Common Trade Names: Midamor
Adult Dosing
- 5-20 mg PO daily
Pediatric Dosing
Not indicated in pediatric patients
Special Populations
- Pregnancy Rating: B
- Lactation risk:
- Renal dosing:
- Avoid if CrCl <50
- CrCl 10-50: reduce dose by 50%
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Anuria, acute or chronic renal insufficiency, diabetic nephropathy
- Hyperkalemia
- Concomitant use of antikaliuretic agents, potassium supplementation/salt substitutes, or other potassium-sparing agents
Adverse Reactions
Serious
- Hyperkalemia
- Cardiac dysrhythmia, palpitations
- Aplastic anemia, neutropenia
- Encephalopathy
- Raised intraocular pressure
Common
- Nausea/vomiting, diarrhea, loss of appetite
- Rash
- Asthenia, muscle cramps
- Cough, dyspnea
- Dizziness
- Headache
Pharmacology
- Half-life: 6-9h
- Metabolism: NOT hepatic
- Excretion: Renal, fecal
Mechanism of Action
- Potassium-sparing diuretic: inhibits epithelial sodium channel in distal renal tubule